Literature DB >> 24965335

Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus.

Honghong Yang1, Xueyuan Heng2, Cuige Liang3, Xiaomeng Liu3, Wenhua Du3, Shoujie Li1, Yueli Wang3, Qingyu Dong3, Wenxia Li3, Zhenyu Pan4, Qian Gong4, Guanqi Gao5.   

Abstract

OBJECTIVE: To investigate prospectively the insulin dose requirements of Chinese patients with type 2 diabetes mellitus treated with either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) therapy during a 2-week therapeutic intervention.
METHODS: Patients with type 2 diabetes mellitus were randomly assigned to MDI or CSII therapy. The effects of the two treatment methods were determined based on blood glucose parameters, total daily insulin dose and rates of hypoglycaemia.
RESULTS: A total of 609 patients were enrolled in the study. Glycaemic goals were achieved after a mean ± SD of 6.90 ± 2.10 and 5.44 ± 2.22 days' treatment in the MDI and CSII groups, respectively. Once stabilized, the mean ± SD total daily insulin doses were 37.12 ± 10.19 IU and 32.58 ± 8.78 IU for the MDI and CSII groups, respectively. Once stabilized, the mean ± SD total basal and bolus doses were 19.46 ± 7.95 IU/day and 17.66 ± 3.53 IU/day for the MDI group, and 22.79 ± 7.55 IU/day and 9.81 ± 2.64 IU/day for the CSII group, respectively. There were significant differences in the total, basal and bolus insulin doses between the two groups.
CONCLUSION: CSII therapy may be considered as an effective method to achieve good glycaemic control in Chinese patients with type 2 diabetes mellitus.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Type 2 diabetes mellitus; continuous subcutaneous insulin infusion; multiple daily injections

Mesh:

Substances:

Year:  2014        PMID: 24965335     DOI: 10.1177/0300060514533523

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

Review 1.  Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies.

Authors:  Guido Freckmann; Sina Buck; Delia Waldenmaier; Bernhard Kulzer; Oliver Schnell; Ulrich Gelchsheimer; Ralph Ziegler; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2020-06-01

Review 2.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

3.  Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes.

Authors:  Fu-Ping Lyu; Bing-Kun Huang; Wei-Juan Su; Fang-Fang Yan; Jin-Yang Zeng; Zheng Chen; Yu-Xian Zhang; Shun-Hua Wang; Yin-Xiang Huang; Mu-Lin Zhang; Xiu-Lin Shi; Ming-Zhu Lin; Xue-Jun Li
Journal:  Diabetes Ther       Date:  2020-02-04       Impact factor: 2.945

4.  Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Authors:  Heng Wan; Defu Zhao; Jie Shen; Lu Lu; Tong Zhang; Zhi Chen
Journal:  J Diabetes Res       Date:  2015-12-21       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.